Skip to main content

Table 3 Perinatal mortality (stillbirths plus neonatal deaths) by exposure group

From: Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia

 

Artemether-lumefantrine

(N = 475)

Sulphadoxine-pyrimethamine

(N = 480)

Perinatal mortality (primary outcome) - n (%)

20 (4.2)

24 (5.0)

   Asymptotic 95% CI

2.4 - 6.0

3.1 - 6.9

   Pearson-Clopper 95% CI

2.6 - 6.4

3.2 - 7.3

   Stillbirth - n (%)

9 (1.9)

13 (2.7)

   Neonatal death ≤7 days after birth - n (%)

11 (2.3)

11 (2.3)

 

Exposure to anti-malarial agent(s) during first trimester*

 

AL only (N = 135)

AL + SP (N = 7)

SP or/and quinine (N = 129)

None (N = 644)

Unknown (N = 40)

Perinatal mortality - n (%)

6 (4.4)

1 (14.3)

5 (3.9)

31 (4.8)

1 (2.5)

   Stillbirth (>28 weeks gestation)

2 (1.5)

0 (0)

3 (2.3)

17 (2.6)

0 (0)

   Death ≤7 days after birth

4 (3.0)

1 (14.3)

2 (1.6)

14 (2.2)

1 (2.5)

  1. Enrolled population: newborns and stillbirths.
  2. Perinatal mortality: stillbirth or early neonatal death within 7 days after birth.
  3. AL = artemether-lumefantrine; CI = confidence interval; SP = sulphadoxine-pyrimethamine.
  4. * Data from newborns and stillbirths with known delivery status.